Chengyou Liu

Chengyou Liu

Auto-generated profile, based on publicly available information

Chengyou Liu

Affiliation Department of Electrical and Computer Engineering, University of Manitoba, Winnipeg, Manitoba, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
ARA. S. M. Zisanur Rahman
A. S. M. Zisanur Rahman
CLChengyou Liu
Chengyou Liu
HSHunter Sturm
Hunter Sturm
AHAndrew Hogan
Andrew Hogan
RDRebecca Davis
Rebecca Davis
SCSilvia Cardona
Silvia Cardona
Screening for novel antibacterial compounds in small molecule libraries has a low success rate. We applied machine learning (ML)-based virtual screening for antibacterial activity and evaluated its predictive power by experimental validation. We first binarized 29,537 compounds according to their growth inhibitory activity (hit rate 0.87%) against the antibiotic-resistant bacterium Burkholderia cenocepacia and described their molecular features with a directed-message passing neural network (D-MPNN). Then, we used the data to train an ML model that achieved a receiver operating characteristic (ROC) score of 0.823 on the test set. Finally, we predicted antibacterial activity in virtual libraries corresponding to 1,614 compounds from the Food and Drug Administration (FDA)-approved list and 224,205 natural products. Hit rates of 26% and 12%, respectively, were obtained when we tested the top-ranked predicted compounds for growth inhibitory activity against B. cenocepacia, which represents at least a 14-fold increase from the previous hit rate. In addition, more than 51% of the predicted antibacterial natural compounds inhibited ESKAPE pathogens showing that predictions expand beyond the organism-specific dataset to a broad range of bacteria. Overall, the developed ML approach can be used for compound prioritization before screening, increasing the typical hit rate of drug discovery.